Drug Trial Radar · NCT03614234
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Nov 13, 2018
Primary completion
Apr 13, 2026
Study completion Apr 13, 2026
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have successfully completed PB-102-F50.
Conditions
- Fabry Disease
Interventions
pegunigalsidase alfaDrug
Recombinant human alpha galactosidase A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of treatment-related adverse eventsTime frame: Throughout the study, 364 weeks
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
UAB Medicine
Birmingham, Alabama
Emory University School of Medicine
Atlanta, Georgia
University of Iowa Hospitals and Clinica
Iowa City, Iowa
Infusion Associates
Grand Rapids, Michigan
Renal Disease Research Institute, LLC
Dallas, Texas
University of Utah Hospitals & Clinics
Salt Lake City, Utah
O & O Alpan
Fairfax, Virginia
UZ Antwerpen
Edegem, Belgium
Fakultní poliklinika Všeobecné fakultní nemocnice v Praze
Prague, Czechia
Medical Endocrinology PE 2132, Rigshospitalet
Copenhagen, Denmark
Azienda Ospedaliera Universitaria "Federico II"
Naples, Via Pansini, Italy
Helse Bergen HF Haukeland Universitetssykehus
Bergen, Norway
Addenbrooke's Hospital
Cambridge, United Kingdom
The Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.